Beneficial effects of costimulatory blockade with anti-inducible costimulator antibody in conjunction with CTLA4Ig on prevention of islet xenograft rejection from rat to mouse

Transplantation

Volumn 78, Issue 11, 2004, Pages 1590-1596

  Nabeyama, Kentaroh ^a   Yasunami, Yohichi ^a   Toyofuku, Atsushi ^a   Nakano, Masahiko ^a   Satoh, Masayuki ^a   Matsuoka, Nobuhide ^a   Ono, Junko ^a   Kamada, Masafumi ^b   Uede, Toshimitsu ^c   Todo, Satoru ^d   Ikeda, Seiyo ^a  

^a FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JT Inc   (Japan)

^c HOKKAIDO UNIVERSITY   (Japan)

^d HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Anti ICOS antibody rejection; ICOS; Islet xenotransplantation

Indexed keywords

ANTIBODY; B7 ANTIGEN; CD28 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IMMUNOGLOBULIN G2A;

ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; DIABETES MELLITUS; FLOW CYTOMETRY; GRAFT REJECTION; GRAFT SURVIVAL; HUMORAL IMMUNITY; LIVER; MALE; MOUSE; NONHUMAN; ORGAN DONOR; PANCREAS ISLET; PRIORITY JOURNAL; RAT; RECIPIENT; SIGNAL TRANSDUCTION; SURVIVAL TIME; T LYMPHOCYTE; TISSUE TRANSPLANTATION; XENOGRAFT; XENOTRANSPLANTATION;

ANIMALS; ANTIBODIES; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CD4-POSITIVE T-LYMPHOCYTES; GRAFT REJECTION; GRAFT SURVIVAL; IMMUNOCONJUGATES; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MICE; MICE, INBRED C57BL; RATS; RATS, INBRED LEW; TRANSPLANTATION, HETEROLOGOUS;

EID: 10644229153     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.TP.0000144054.46946.CF     Document Type: Article

References (26)

1. Shapiro AM, Lakey JRT, Ryan EA, et al. Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 2000; 343: 230.
2. Boussiotis VA, Freeman GJ, Gribben JG, et al. The role of B7-1/B7-2: CD28/CTLA-4 pathways in the prevention of anergy, induction of productive immunity and down-regulation of the immune response. Immunol Rev 1996; 153: 5.
3. Linsley PS, Wallace PM, Johnson J, et al. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 1992; 257: 792.
4. Hutloff A, Dittrich AM, Beier KC, et al. ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28. Nature 1999; 397: 263.
5. Yoshinaga SK, Whoriskey JS, Khare SD, et al. T-cell co-stimulation through B7RP-1 and ICOS. Nature 1999; 402: 827.
6. Dong C, Juedes AE, Temann UA, et al. ICOS co-stimulatory receptor is essential for T-cell activation and function. Nature 2001; 409: 97.
7. McAdam AJ, Greenwald RJ, Levin MA, et al. ICOS is critical CD40-mediated antibody class switching. Nature 2001; 409: 102.
8. Tafuri A, Shahinian A, Bladt F, et al. ICOS is essential for effective T-helper-cell responses. Nature 2001; 409: 105.
9. Sutton R, Peters M, Mcshane P, et al. Isolation of rat pancreatic islets by ductal injection of collagenase. Transplantation 1986; 42: 689.
10. Okada T, Ono J, Takaki R, et al. Simple method for the collection of pancreatic islets by the use of Ficoll-Conray gradient. Endocrinol Japan 1979; 26: 495.
11. + in the liver in association with intrahepatic islet xenograft rejection from rat to mouse: Prevention of rejection with anti-IL-2Rβ monoclonal antibody treatment. Transplantation 1997; 64: 633.
12. Sakamoto S, Tezuka K, Tsuji T, et al. AILIM/ICOS: Its expression and functional analysis with monoclonal antibodies. Hybridoma 2001; 20: 293.
13. Nakagawa I, Murakami M, Ijima K, et al. Persistent and secondary adenovirus-mediated hepatic gene expression using adenovirus vector. Hum Gene Ther 1998; 9: 1739.
14. Lenschow DJ, Zeng Y, Thistlethwaite JR, et al. Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 1992; 257: 789.
15. Tran HM, Nickerson PW, Patel A, et al. Short-term suppression of the xeno-immune response with mCTLA4-Fc treatment. Xenotransplantation 1997; 4: 222.
16. +T cell apoptosis but not immune deviation. Transplantation 2000; 69: 1176.
17. Nakamura Y, Yasunami Y, Satoh M, et al. Acceptance of islet allografts in the liver of mice by blockade of an inducible costimulator. Transplantation 2003; 75: 1115.
18. Turka LA, Linsley PS, Lin H, et al. T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci U S A 1992; 89: 11102.
19. Kirk AD, Harlan DM, Armstrong NN, et al. CTLA4Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc Natl Acad Sci U S A 1997; 94: 8789.
20. Alegre ML, Frauwirth KA, Thompson CB. T-cell regulation by CD28 and CTLA-4. Nat Rev Immunol 2001; 1: 220.
21. Wolf LA, Coulombe M, Gill RG. Donor antigen-presenting cell-independent rejection of islet xenografts. Transplantation 1995; 60: 1164.
22. Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol 2002; 2: 116.
23. + T-lymphocyte-deficient recipients. Transplant Proc 1993; 25(1): 961.
24. + T- lymphocytes. Transplant Proc 1992; 24(6): 2877.
25. Krieger NR, Ito H, Fathman CG. Rat pancreatic islet and skin xenograft survival in CD4 and CD8 knockout mice. J Autoimmun 1998; 10: 309.
26. + Vα14 natural killer T cells are essential for acceptance of rat islet xenografts in mice. J Clin Invest 2000; 105: 1761.